体外膜氧合中肝素相关性血小板减少症的处理  

Management of heparin-associated thrombocytopenia in extracorporeal membrane oxygenation

作　　者：许华 王勇强[1] Xu Hua;Wang Yongqiang(Department of Critical Care Medicine,Tianjin First Center Hospital,Tianjin 300192,China)

机构地区：[1]天津市第一中心医院重症医学科,300192

出　　处：《中华重症医学电子杂志》2020年第2期156-159,共4页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

摘　　要：肝素诱导的血小板减少症(HIT)是一种临床应用肝素过程中出现最多的非出血性免疫相关的并发症,在体外膜氧合(ECMO)使用过程中发生的概率不高,但致命性极强。因此ECMO使用过程中预防HIT极其重要。此外,掌握HIT发生时的处理策略并在该并发症发生早期给予正确的干预是降低ECMO并发HIT患者死亡的关键。本文旨在对ECMO中HIT的处理作简要分析。Heparin induced thrombocytopenia(HIT)is a non-hemorrhagic immune-related complication that occurs most frequently in the clinical application of heparin.The probability of occurrence of HIT is not high during the use of extracorporeal membrane oxygenation(ECMO),but it is extremely lethal.Therefore,it is extremely important to prevent the occurrence of HIT during the use of ECMO.In addition,being familiar with the treatment strategy for HIT and giving proper intervention early when this complication occurs are the keys to reducing the mortality of patients.This article briefly analyzes the management of heparin-related thrombocytopenia in extracorporeal membrane oxygenation.

关 键 词：肝素 血小板减少 体外膜氧合作用 预防 处理 

分 类 号：R558.2[医药卫生—血液循环系统疾病]